ere less likely to be colonized by the bacteria in the mucosa of the
terminal rectum at harvest (OR=0.014, p<0.0001), resulting in a vaccine
colonization efficacy of 98.3%. A two-dose vaccination was used to evaluate
hide contamination in the feedlot. Hides were sampled for E. coli O157:H7
contamination twice in the feedlot and immediately before and after animals
were shipped to the abattoir. This same study also found a statistically
significant reduction in the likelihood of vaccinated animals having
contaminated hides. Additionally, pen-level prevalence following a two dose
vaccination was assessed in a feedlot study. Vaccinated pens were less
likely than unvaccinated pens to test positive (OR=0.59, p<0.004) using the
"These results provide compelling evidence that vaccination of cattle
with the Bioniche E. coli O157:H7 cattle vaccine has the potential to be an
effective pre-slaughter intervention for the reduction of E. coli O157:H7
shedding, colonization, hide contamination, and pen-level prevalence,"
concluded Dr. Rogan.
Food recalls due to E. coli O157:H7 contamination continue to be a
concern in beef, produce and prepared food. On-farm interventions to reduce
the shedding of E. coli O157:H7 by cattle, such as vaccination, may assist
in reducing the potential for food and water contamination and the
resulting human illnesses and deaths.
Approximately 100,000 cases of human infection with the E. coli O157:H7
organism are reported each year in North America. 2% to 7% of those people
develop hemolytic uremic syndrome (HUS), a disease characterized by kidney
failure (in recent outbreaks, this percentage has risen to as high as 16%).
Five percent of HUS patients die, many of them children and senior
citizens, whose kidneys are more sensitive to damage.
In addition to being infected by contaminated food or water,
individuals can become infected from E. coli O157:H7 by visiting animal
exhibits. Petting zoos, fairs, and agri
Page: 1 2 3 4 Related medicine news :1
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference2
. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production3
. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia4
. Bioniche Presents Pre-Clinical Research at Two International Conferences5
. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform6
. Bioniche Reports Fiscal 2008 Third Quarter7
. Bioniche Appoints U.S. President of Food Safety8
. Bioniche Reports the Passing of its Board Chair9
. Bioniche Converts a Portion of its Debt to Equity10
. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy11
. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution